PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Ampicillin	104-114	AFA	Homo sapiens	8-11
33928264-3	2021	However, in marked contrast, Ala-Phe-Ala (AFA) was surprisingly found to be non-aggregative and could be solubilized at millimolar concentrations.	Ala-Phe-Ala	29-40	AFA	Homo sapiens	42-45
33928264-5	2021	We demonstrate an unexpectedly high water solubility of AFA reaching 672 mM, two orders of magnitude higher than reported previously.	Water	36-41	AFA	Homo sapiens	56-59
33114029-7	2020	The impact of the steel-MgO composite material on the composition of the aluminum alloy regarding the type, size, and quantity of the formed precipitations was investigated with the aid of ASPEX PSEM/AFA and SEM/EBSD.	mgo	24-27	AFA	Homo sapiens	189-203
32407616-3	2020	Herein, we demonstrate that a three-dimensional all-fiber aerogel (3D AFA), which can float on water surface and continuously self-pump water.	Water	95-100	AFA	Homo sapiens	70-73
32407616-3	2020	Herein, we demonstrate that a three-dimensional all-fiber aerogel (3D AFA), which can float on water surface and continuously self-pump water.	Water	136-141	AFA	Homo sapiens	70-73
32407616-6	2020	Besides, the designed 3D AFA possesses sustainable stability and self-cleaning function to restrain salt deposition, and there is no significant change in the evaporation performance after many cycles in the case of seawater treatment.	Salts	100-104	AFA	Homo sapiens	25-28
31064043-12	2019	Conclusion: Our results suggest that the herein-described AFA score is a useful tool for predicting SdHCP before aneurysm obliteration.	sdhcp	100-105	AFA	Homo sapiens	58-61
31412510-2	2019	The chemical nature of the organic scaffold and the type and abundance of oxygen-containing functional groups of the synthetic humic substances (A-FA and A-HA) are revealed by a series of examinations.	Oxygen	74-80	AFA	Homo sapiens	145-149
31412510-2	2019	The chemical nature of the organic scaffold and the type and abundance of oxygen-containing functional groups of the synthetic humic substances (A-FA and A-HA) are revealed by a series of examinations.	Humic Substances	127-143	AFA	Homo sapiens	145-149
28358256-1	2017	Magnetic, pH and temperature-sensitive, poly(N-isopropylacrylamide) (PNIPAM)-based nanocomposites with fluorescent properties were synthesized by free radical copolymerization-cross linking of NIPAM, N,N-dimethylaminoethyl methacrylate (DMAEMA) and 4-acrylamidofluorescein (AFA).	poly-N-isopropylacrylamide	40-67	AFA	Homo sapiens	274-277
28358256-1	2017	Magnetic, pH and temperature-sensitive, poly(N-isopropylacrylamide) (PNIPAM)-based nanocomposites with fluorescent properties were synthesized by free radical copolymerization-cross linking of NIPAM, N,N-dimethylaminoethyl methacrylate (DMAEMA) and 4-acrylamidofluorescein (AFA).	poly-N-isopropylacrylamide	69-75	AFA	Homo sapiens	274-277
32667898-12	2020	CONCLUSIONS: This AFA model for assessing the true ovarian reserve was easier, more cost-effective and more objective than our original AAFA model.	aafa	136-140	AFA	Homo sapiens	18-21
32521810-4	2020	The antioxidant curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-2,5-dione], glycosinolate of sulforaphane (broccoli) or AFA (Aphanizomenon flos) extract promote beneficial effects in patients.	Curcumin	16-24	AFA	Homo sapiens	132-135
32521810-4	2020	The antioxidant curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-2,5-dione], glycosinolate of sulforaphane (broccoli) or AFA (Aphanizomenon flos) extract promote beneficial effects in patients.	glycosinolate	88-101	AFA	Homo sapiens	132-135
32521810-4	2020	The antioxidant curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-2,5-dione], glycosinolate of sulforaphane (broccoli) or AFA (Aphanizomenon flos) extract promote beneficial effects in patients.	sulforaphane	105-117	AFA	Homo sapiens	132-135
32521810-14	2020	The long-term administration with curcuminoids, glycosinolate of sulforaphane, and AFA bluegreen algae extract also increased the total number of CD34-HSC cells after seven or 38 days of consecutive of administration in healthy subjects.	bluegreen	87-96	AFA	Homo sapiens	83-86
30855607-1	2019	A direct NO-releasing reaction of nitrite catalyzed by [N(afaCy)3Fe(OTf)]+ (afa (azafulvene-amine); OTf (trifluoromethanesulfonate); Cy (cyclohexyl)) was investigated using density functional theory (DFT) with D3 dispersion correction.	Nitrites	34-41	AFA	Homo sapiens	58-61
30855607-1	2019	A direct NO-releasing reaction of nitrite catalyzed by [N(afaCy)3Fe(OTf)]+ (afa (azafulvene-amine); OTf (trifluoromethanesulfonate); Cy (cyclohexyl)) was investigated using density functional theory (DFT) with D3 dispersion correction.	azafulvene-amine	81-97	AFA	Homo sapiens	58-61
30855607-1	2019	A direct NO-releasing reaction of nitrite catalyzed by [N(afaCy)3Fe(OTf)]+ (afa (azafulvene-amine); OTf (trifluoromethanesulfonate); Cy (cyclohexyl)) was investigated using density functional theory (DFT) with D3 dispersion correction.	trifluoromethanesulfonic acid	105-130	AFA	Homo sapiens	58-61
29522788-9	2019	The urinary afamin to creatinine ratio (Afa/Cre) was significantly higher in patients who progressed to a more severe DN stage or had early renal decline than in patients who did not.	afamin	12-18	AFA	Homo sapiens	40-43
29522788-9	2019	The urinary afamin to creatinine ratio (Afa/Cre) was significantly higher in patients who progressed to a more severe DN stage or had early renal decline than in patients who did not.	Creatinine	22-32	AFA	Homo sapiens	40-43
28069519-1	2017	The objective of this study was to establish that the denaturing fixative, formalin and acetic acid (AFA), is equivalent to neutral-buffered formalin (NBF) on the nCounter system using the Prosigna assay.	Acetic Acid	88-99	AFA	Homo sapiens	101-104
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Amoxicillin	116-127	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Amoxicillin	116-127	AFA	Homo sapiens	235-238
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Clavulanic Acid	128-143	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Clavulanic Acid	128-143	AFA	Homo sapiens	235-238
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Nalidixic Acid	145-159	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Ceftriaxone	173-184	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Ceftriaxone	173-184	AFA	Homo sapiens	235-238
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	esbl	199-203	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	drabc	12-17	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	drabc	12-17	AFA	Homo sapiens	235-238
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Cefotaxime	249-259	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Cefuroxime	261-271	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Ciprofloxacin	273-286	AFA	Homo sapiens	8-11
26518125-11	2015	iha and afa/draBC genes were more frequent in resistant isolates than the susceptible ones; for iha, in ampicillin, amoxicillin/clavulanic acid, nalidixic acid, cefuroxime, ceftriaxone resistant and ESBL and MDR positive isolates; for afa/draBC, in cefotaxime, cefuroxime, ciprofloxacin, trimethoprim/sulfamethoxazole resistant and ESBL and MDR positive isolates, this trend was observed.	Trimethoprim, Sulfamethoxazole Drug Combination	288-317	AFA	Homo sapiens	8-11
20224912-3	2010	To unveil the nature of interaction of M, quantum chemical studies are carried out on the palindromic tripeptides Alanine-Phenylalanine-Alanine (AFA) and Alanine-Valine-Alanine (AVA) present in Acutohaemolysin and Piratoxin-II at B3LYP/6-311G** level of theory.	alanine-phenylalanine-alanine	114-143	AFA	Homo sapiens	145-148
21207947-1	2011	We report here a synthetic route to bis(N,N"-aryl)-6-aminofulvene-2-aldimine (AFA) ligand systems, specifically Ph(2)-AFAH and Dip(2)-AFAH.	bis(n,n"-aryl)-6-aminofulvene-2-aldimine	36-76	AFA	Homo sapiens	78-81
21207947-1	2011	We report here a synthetic route to bis(N,N"-aryl)-6-aminofulvene-2-aldimine (AFA) ligand systems, specifically Ph(2)-AFAH and Dip(2)-AFAH.	dip(2)-afah	127-138	AFA	Homo sapiens	78-81
21207947-4	2011	The reactions of the AFA compounds Ph(2)-AFAH and Dip(2)-AFAH with ZnMe(2) and AlMe(3) have also been investigated, and the results of these reactions are described here.	(2)-afah	37-45	AFA	Homo sapiens	21-24
21207947-4	2011	The reactions of the AFA compounds Ph(2)-AFAH and Dip(2)-AFAH with ZnMe(2) and AlMe(3) have also been investigated, and the results of these reactions are described here.	dip(2)-afah	50-61	AFA	Homo sapiens	21-24
21207947-4	2011	The reactions of the AFA compounds Ph(2)-AFAH and Dip(2)-AFAH with ZnMe(2) and AlMe(3) have also been investigated, and the results of these reactions are described here.	znme	67-71	AFA	Homo sapiens	21-24
21207947-4	2011	The reactions of the AFA compounds Ph(2)-AFAH and Dip(2)-AFAH with ZnMe(2) and AlMe(3) have also been investigated, and the results of these reactions are described here.	alpha-acetyllysine methyl ester	79-83	AFA	Homo sapiens	21-24
20224912-7	2010	The preferred secondary structural configuration and conformational properties of AVA and AFA also validate the strong interaction of fatty acid with Phenylalanine.	Phenylalanine	150-163	AFA	Homo sapiens	90-93
20224912-7	2010	The preferred secondary structural configuration and conformational properties of AVA and AFA also validate the strong interaction of fatty acid with Phenylalanine.	Fatty Acids	134-144	AFA	Homo sapiens	90-93
20467588-1	2010	Indacaterol (Onbrez), previously known as QAB-149-AFA, is a novel ultra-long-acting beta2-adrenoceptor agonist that was recently approved by the European Commission as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).	indacaterol	0-11	AFA	Homo sapiens	42-53
20184301-0	2010	Conformations of phenylalanine in the tripeptides AFA and GFG probed by combining MD simulations with NMR, FTIR, polarized Raman, and VCD spectroscopy.	Phenylalanine	17-30	AFA	Homo sapiens	50-53
20184301-0	2010	Conformations of phenylalanine in the tripeptides AFA and GFG probed by combining MD simulations with NMR, FTIR, polarized Raman, and VCD spectroscopy.	tripeptides	38-49	AFA	Homo sapiens	50-53
20184301-4	2010	The results of this analysis indicate that the F residue predominantly populates the beta-strand (beta) and polyproline II (PPII) conformations in both AFA and GFG.	polyproline ii	108-122	AFA	Homo sapiens	152-155
20467588-1	2010	Indacaterol (Onbrez), previously known as QAB-149-AFA, is a novel ultra-long-acting beta2-adrenoceptor agonist that was recently approved by the European Commission as a new once-daily maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).	indacaterol	13-19	AFA	Homo sapiens	42-53
19500686-4	2009	We show that norepinephrine affects the production and release of Dr fimbriae in Afa/Dr DAEC WT-IH11128 bacteria.	Norepinephrine	13-27	AFA	Homo sapiens	81-84
17627600-0	2007	A small tripeptide AFA undergoes two state cooperative conformational transitions: implications for conformational biases in unfolded states.	tripeptide K-26	8-18	AFA	Homo sapiens	19-22
17263404-1	2007	Photoelectron spectra of adenine-formic acid (AFA(-)) and 9-methyladenine-formic acid (MAFA(-)) anionic complexes have been recorded with 2.540 eV photons.	adenine-formic acid	25-44	AFA	Homo sapiens	46-49
17263404-4	2007	The neutral complexes form cyclic hydrogen bonds, and the most stable dimers are bound by 17.7 and 16.0 kcal/mol for AFA and MAFA, respectively.	Hydrogen	34-42	AFA	Homo sapiens	117-120
17263404-5	2007	The theoretical results indicate that the excess electron in both AFA(-) and MAFA(-) occupies a pi* orbital localized on adenine/9-methyladenine, and the adiabatic stability of the most stable anions amounts to 0.67 and 0.54 eV for AFA(-) and MAFA(-), respectively.	Adenine	121-128	AFA	Homo sapiens	66-69
17263404-5	2007	The theoretical results indicate that the excess electron in both AFA(-) and MAFA(-) occupies a pi* orbital localized on adenine/9-methyladenine, and the adiabatic stability of the most stable anions amounts to 0.67 and 0.54 eV for AFA(-) and MAFA(-), respectively.	Adenine	121-128	AFA	Homo sapiens	78-81
18590157-6	2008	Aspiration through an AFA FPP-15 aerosol filter is a suitable device for air chloramphenicol sampling.	Chloramphenicol	77-92	AFA	Homo sapiens	22-25
17263404-5	2007	The theoretical results indicate that the excess electron in both AFA(-) and MAFA(-) occupies a pi* orbital localized on adenine/9-methyladenine, and the adiabatic stability of the most stable anions amounts to 0.67 and 0.54 eV for AFA(-) and MAFA(-), respectively.	9-methyladenine	129-144	AFA	Homo sapiens	66-69
17263404-5	2007	The theoretical results indicate that the excess electron in both AFA(-) and MAFA(-) occupies a pi* orbital localized on adenine/9-methyladenine, and the adiabatic stability of the most stable anions amounts to 0.67 and 0.54 eV for AFA(-) and MAFA(-), respectively.	9-methyladenine	129-144	AFA	Homo sapiens	78-81
17627600-2	2007	In this context, it is surprising that even a short tripeptide like AFA samples folded/ordered conformation as demonstrated recently by NMR experiments of the peptide in aqueous solution at 280 K. In this paper, we present molecular dynamics simulation of the peptide in explicit water using OPLS-AA/L all-atom force field.	tripeptide K-26	52-62	AFA	Homo sapiens	68-71
17627600-2	2007	In this context, it is surprising that even a short tripeptide like AFA samples folded/ordered conformation as demonstrated recently by NMR experiments of the peptide in aqueous solution at 280 K. In this paper, we present molecular dynamics simulation of the peptide in explicit water using OPLS-AA/L all-atom force field.	Water	280-285	AFA	Homo sapiens	68-71
16801739-14	2006	On the contrary, the increase of AFA revealed a recovery of fat-metabolism (corresponding to RQ decrease) and lipid/carbohydrates oxidation improvement, only in the presence, at the same time, of O2 consumption increase.	Carbohydrates	116-129	AFA	Homo sapiens	33-36
16801739-14	2006	On the contrary, the increase of AFA revealed a recovery of fat-metabolism (corresponding to RQ decrease) and lipid/carbohydrates oxidation improvement, only in the presence, at the same time, of O2 consumption increase.	Oxygen	196-198	AFA	Homo sapiens	33-36
12033946-3	2002	The importance of the positive charge on the 1-nitrogen in binding is established by the observation that AIA binds >30 000-fold more tightly to the EU complex than the corresponding neutral tetrahydrofuran (F) abasic site product analogue (AFA).	1-nitrogen	45-55	AFA	Homo sapiens	244-247
20641346-7	2004	2-(2-(Dimethylaminomethyl)phenylthio)-5-fluorophenylamine (AFA), a novel PET radioligand, can be labeled with either (11)C or (18)F. In vitro, it has shown rapid brain uptake kinetics as well as a high affinity for SERT, with lower affinities for the norepinephrine transporter (NET) and dopamine transporter (DAT).	2-(2-(dimethylaminomethyl)phenylthio)-5-fluorophenylamine	0-57	AFA	Homo sapiens	59-62
16245933-2	2005	Here we report that the tripeptide Ala-Phe-Ala (AFA) in aqueous solution preferentially forms an inverse gamma-turn.	tripeptide K-26	24-34	AFA	Homo sapiens	48-51
16245933-2	2005	Here we report that the tripeptide Ala-Phe-Ala (AFA) in aqueous solution preferentially forms an inverse gamma-turn.	Ala-Phe-Ala	35-46	AFA	Homo sapiens	48-51
16245933-7	2005	Since for AFA an extended beta-strand was also reported [Eker, F., Griebenow, K., Cao, X., Nafie, L. A., and Schweitzer-Stenner, R. (2004) Proc.	nafie	91-96	AFA	Homo sapiens	10-13
15331605-0	2004	High resolution studies of the Afa/Dr adhesin DraE and its interaction with chloramphenicol.	Chloramphenicol	76-91	AFA	Homo sapiens	31-34
15130118-4	2004	We analysed the interactions of Afa/Dr DAEC with the CEACAMs using CEACAM-expressing CHO and HeLa cells.	ceacam	53-59	AFA	Homo sapiens	32-35
16363668-1	2005	PURPOSE: Using anterior segment fluorescein angiography(AFA), we evaluated the relationship between the effect of vitrectomy combined with endophotocoagulation for neovascular glaucoma and the postoperative angiographic changes.	Fluorescein	32-43	AFA	Homo sapiens	56-59
15213113-5	2004	We show that the receptor for Afa/Dr adhesins, glycosylphosphatidylinositol-anchored CD55; the raft marker, ganglioside GM1; and VIP21/caveolin are all recruited around adhering Dr-positive bacteria.	Gangliosides	108-119	AFA	Homo sapiens	30-33
15213113-5	2004	We show that the receptor for Afa/Dr adhesins, glycosylphosphatidylinositol-anchored CD55; the raft marker, ganglioside GM1; and VIP21/caveolin are all recruited around adhering Dr-positive bacteria.	G(M1) Ganglioside	120-123	AFA	Homo sapiens	30-33
9854632-2	1998	Morphine and adrenaline caused different changes in production of active forms of oxygen (AFA) and antioxidant activity of the enzymes superoxide dismutase and glutathione reductase in neutrophils, monocytes, and lymphocytes in human peripheral blood.	Morphine	0-8	AFA	Homo sapiens	90-93
9854632-2	1998	Morphine and adrenaline caused different changes in production of active forms of oxygen (AFA) and antioxidant activity of the enzymes superoxide dismutase and glutathione reductase in neutrophils, monocytes, and lymphocytes in human peripheral blood.	Epinephrine	13-23	AFA	Homo sapiens	90-93
9854632-2	1998	Morphine and adrenaline caused different changes in production of active forms of oxygen (AFA) and antioxidant activity of the enzymes superoxide dismutase and glutathione reductase in neutrophils, monocytes, and lymphocytes in human peripheral blood.	Oxygen	82-88	AFA	Homo sapiens	90-93
1712505-1	1991	The active forms of oxygen (AFA) participate in modulation of mediation processes in patients with systemic lupus erythematosus.	Oxygen	20-26	AFA	Homo sapiens	28-31
35143806-6	2022	We combined EBTP with four TKIs (Bosutinib, Apatinib, Afatinib and Erlotinib) to treat HepG2 cells and CompuSyn software analysis suggested that EBTP/Afatinib(Afa)shows the best synergistic inhibitory effect.	ebtp	12-16	AFA	Homo sapiens	159-162
35143806-6	2022	We combined EBTP with four TKIs (Bosutinib, Apatinib, Afatinib and Erlotinib) to treat HepG2 cells and CompuSyn software analysis suggested that EBTP/Afatinib(Afa)shows the best synergistic inhibitory effect.	ebtp	145-149	AFA	Homo sapiens	159-162
35143806-10	2022	Further, the supernatant of HepG2 cells treated with EBTP/Afa blocks the intracellular downstream signal transduction shared by VEGF and EGFR in HUVECs.	ebtp	53-57	AFA	Homo sapiens	58-61
35143806-11	2022	Finally, EBTP/Afa significantly inhibits tumor growth and angiogenesis in vivo.	ebtp	9-13	AFA	Homo sapiens	14-17
35143806-12	2022	To conclude, EBTP/Afa targets VEGF and EGFR signaling pathways in liver cancer cells and tumor vasculature, thereby inhibiting the proliferation, motion and angiogenesis of liver cancer cells.	ebtp	13-17	AFA	Homo sapiens	18-21